Pfizer Expects to Produce 80 Mln Courses of COVID-19 Antiviral Pill – CNBC Reporter Tweet

Pfizer Inc estimates it can manufacture 80 million treatment courses of its experimental COVID-19 antiviral drug, up from a previous forecast of 50 million, a CNBC reporter tweeted on Monday. Read More